Analyst Ami Fadia from Needham maintained a Buy rating on Neurocrine and keeping the price target at $184.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ami Fadia’s rating is based on Neurocrine’s diverse development pipeline and strategic approach toward innovative therapies. The company has outlined a robust plan to expand its portfolio, including a new CRF2 agonist asset (NBIP-2118), targeted for obesity treatment, which stands out for its design focusing on weight loss while preserving muscle. This asset is expected to enter clinical trials in the first half of 2026.
Neurocrine’s muscarinic portfolio also plays a significant role in the optimistic outlook, with ongoing Phase 3 trials for direclidine in schizophrenia and Phase 2 studies for bipolar mania, as well as Phase 3 studies for osavampator in major depressive disorder. Collectively, these initiatives underline the company’s focus on addressing critical unmet medical needs while taking steps to sustain shareholder value over the medium term. The diversification into multiple therapeutic areas further strengthens the potential for achieving favorable outcomes.
According to TipRanks, Fadia is a 5-star analyst with an average return of 21.9% and a 53.28% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Neurocrine, and Harmony Biosciences Holdings.
In another report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $180.00 price target.